I specialize in the development of biologicals for the treatment and detection of epithelial ovarian cancers. In 2018 I started DAROU biologics. Our first product, ARPNS, was recently patented. ARPNS is a nanomolecule that can detect a wide variety of ovarian tumors noninvasively with 98% accuracy both in vivo and in vitro.